01.05.12
Harlan Laboratories has appointed Doug Vaughan as chief financial officer and David Broecker as president, Research Models & Services (RMS). Both will be a part of the management committee and will report to Hans Thunem, chief executive officer of Harlan Laboratories.
Mr. Vaughan is an experienced global finance executive, across multiple industries and business models. Most recently, he served as vice president of finance for Ingersoll Rand in the consumer products industry. Prior to that, he served as chief financial officer for International Specialty Products, a privately held global specialty chemical company. He also spent 14 years with Honeywell International in roles encompassing controllership, sourcing, procurement, pricing and contracts, acquisitions and finance.
Mr. Broecker is an experienced biopharmaceutical executive. Most recently, he was chief executive officer of BioCritica, a private biotechnology company focused on the development and commercialization of products for the critical care market. From 2001 to 2009, Mr. Broecker was a senior executive at Alkermes, and spent the last three years as its president and chief executive officer. During his tenure, he led the strategic transformation of Alkermes from a partner-driven, drug delivery company to an integrated biopharmaceutical company with the capabilities to develop and commercialize proprietary products.
“In spite of challenging preclinical markets, Harlan is experiencing growth that it intends to accelerate in the coming years. Our activities over the past 12 months have been aimed at becoming an even stronger player in the preclinical segment and to improve the overall quality of our products and services. Doug and David both bring tremendous depth and experience in working with customers and other stakeholders and will be instrumental to those plans,” said Mr. Thunem.
Mr. Vaughan is an experienced global finance executive, across multiple industries and business models. Most recently, he served as vice president of finance for Ingersoll Rand in the consumer products industry. Prior to that, he served as chief financial officer for International Specialty Products, a privately held global specialty chemical company. He also spent 14 years with Honeywell International in roles encompassing controllership, sourcing, procurement, pricing and contracts, acquisitions and finance.
Mr. Broecker is an experienced biopharmaceutical executive. Most recently, he was chief executive officer of BioCritica, a private biotechnology company focused on the development and commercialization of products for the critical care market. From 2001 to 2009, Mr. Broecker was a senior executive at Alkermes, and spent the last three years as its president and chief executive officer. During his tenure, he led the strategic transformation of Alkermes from a partner-driven, drug delivery company to an integrated biopharmaceutical company with the capabilities to develop and commercialize proprietary products.
“In spite of challenging preclinical markets, Harlan is experiencing growth that it intends to accelerate in the coming years. Our activities over the past 12 months have been aimed at becoming an even stronger player in the preclinical segment and to improve the overall quality of our products and services. Doug and David both bring tremendous depth and experience in working with customers and other stakeholders and will be instrumental to those plans,” said Mr. Thunem.